Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Experts attributed those years to a rebound in RSV and flu infections after two years of pandemic precautions. In 2023, U.S.

The U.S. Centers for Disease Control and Prevention (CDC) recommends that all babies be protected from RSV by one of two ...

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

TUESDAY, May 6, 2025 (HealthDay News) -- Newborns can be effectively protected against respiratory syncytial virus (RSV) infection through the use of nirsevimab, a monoclonal antibody treatment ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

The treatment reduced the risk of hospitalization by 83% U.S. babies enjoyed better protection because treatment was prioritized for high-risk infants TUESDAY, May 6, 2025 (HealthDay News ...

Nirsevimab associated with lower odds of RSV-related hospitalization, ICU admission, lower respiratory tract infection incidence.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.